Results 21 to 30 of about 5,304 (170)

Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China

open access: yesTherapeutic Advances in Hematology
Background: Acalabrutinib is a highly selective, latest generation Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia (CLL).
Mengya Li   +6 more
doaj   +2 more sources

Real-World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First-Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study. [PDF]

open access: yesEJHaem
ABSTRACT Background Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...
Burke JM   +10 more
europepmc   +2 more sources

Decision-Making on First-Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi-Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy. [PDF]

open access: yesHematol Oncol
ABSTRACT Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. The introduction of targeted therapies has expanded first‐line treatment options, which differ across multiple relevant dimensions, making therapeutic decisions increasingly challenging.
Sportoletti P   +10 more
europepmc   +2 more sources

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial [PDF]

open access: yes, 2021
PURPOSE: Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability.
Rothbaum, Wayne   +76 more
core   +1 more source

The acalabrutinib-bound BTK kinase domain.

open access: yes, 2023
a. Overall structure of the BTK KD/acalabrutinib complex. Key features of the kinase domain are labeled. Acalabrutinib is shown in yellow sticks and covalently attached to Cys481. Activation loop is colored red with Tyr551 shown in sticks.
Amy H. Andreotti (366314)   +1 more
core   +1 more source

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

open access: yesHaematologica, 2021
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL).
Jennifer R. Brown   +14 more
doaj   +1 more source

FRAILTY ASSESSMENT AS PREDICTOR OF BLEEDING FOR PATIENTS TREATED WITH ACALABRUTINIB

open access: yesHematology, Transfusion and Cell Therapy, 2023
Introduction: The American Society of Clinical Oncology (ASCO) promotes the routine use of a comprehensive geriatric assessment, particularly emphasizing frailty, to identify vulnerabilities not detected in the standard clinical evaluation.
TX Carneiro   +7 more
doaj   +1 more source

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia

open access: yesTherapeutic Advances in Hematology, 2023
Background: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3-related protein (ATR) inhibitor, demonstrated synergistic preclinical ...
Wojciech Jurczak   +13 more
doaj   +1 more source

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

open access: yes, 2023
ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia.
Woyach J. A.   +17 more
core   +1 more source

Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States

open access: yes, 2023
Clinical outcomes in chronic lymphocytic leukemia (CLL) have improved with targeted therapy, including Bruton tyrosine kinase inhibitors such as acalabrutinib. A semi-Markov model with three health states (progression-free, progressed disease, and death)
Priyanka Gaitonde (15203357)   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy